FrancophonIA/ELRC3.0 huggingface dataset:
English: The frequency of isolations of each organism in unvaccinated pigs provided some indication of the prevalence of the agent at the site and, taken in association with experience of pathology, could be considered to provide some support for the classification process.
Danish: Hyppigheden af isolationer af hver organisme hos ikke-vaccinerede svin gav en vis indikation af forekomsten af agensen på stedet og kunne, i forbindelse med erfaring med patologi, betragtes som en støtte for klassifikationsprocessen.
English: The data provided was not considered adequate to support a claim for the P.multocida component (discussed below) therefore a link between production parameters and efficacy for PMA could not be accepted.
Danish: De fremsendte data ansås ikke for tilstrækkelige til at underbygge en påstand om P. multocidakomponenten (diskuteres nedenfor), og en sammenhæng mellem produktionsparametre og effektivitet for PMA kunne derfor ikke accepteres.
English: In addition, Spain considered that an adequate justification had not been provided for including the different serotypes of A.pleuropneumoniae and P. multocida into the same vaccine.
Danish: Spanien vurderede endvidere, at der ikke var blevet forelagt tilstrækkelig begrundelse for at medtage de forskellige serotyper af A. pleuropneumoniae og P. multocida i den samme vaccine.
English: This opinion was supported by opinions gathered by the Applicant/MAH from EDQM and the Chairman of Group 15V.
Danish: Denne vurdering støttedes af udtalelser, som ansøgeren/indehaveren af markedsføringstilladelsen havde indhentet fra EDQM og formanden for gruppe 15V.
English: It was noted by the Committee that the lack of compliance with the GCP requirements weakened the content of the surveillance study essentially.
Danish: Udvalget bemærkede, at den manglende overensstemmelse med GCP-kravene (god klinisk praksis) svækkede indholdet af overvågningsundersøgelsen væsentligt.
English: Specific challenge studies had not been conducted using APP serotype 11 as challenge, therefore Spain had requested confirmation of efficacy of the APP 11 component.
Danish: Der var ikke blevet foretaget specifikke challengeundersøgelser med APP serotype 11 som belastning, og derfor havde Spanien anmodet om en bekræftelse af APP 11-komponentens effektivitet.
English: It is considered that the principle requirements for the demonstration of efficacy are laid down by the Ph. Eur.
Danish: Det vurderes, at de primære krav om påvisning af effektivitet er fastsat i Den Europæiske Farmakopé.
English: The applicant has provided data which confirm that the APP serotypes contained within the product are present in the Member States involved.
Danish: Ansøgeren har forelagt data, som bekræfter, at de APP-serotyper, der indgår i lægemidlet, er til stede i de involverede medlemsstater.
English: Consequently, there do not appear to be additional safety concerns relating to the levels of formaldehyde that may result from administration of product containing formaldehyde at the levels proposed.
Danish: Der synes derfor ikke at være yderligere betænkeligheder med hensyn til sikkerheden i forbindelse med de restkoncentrationer af formaldehyd, der kan følge af indgivelse af et lægemiddel, der indeholder formaldehyd i de foreslåede koncentrationer.
English: Slovak
Danish: Den Slovakiske
English: These tests (Modified Agglutination Test for APP and optical density at 540nm for PMA) had been validated, however further questions were raised concerning the link between the initial antigen levels before inactivation (CFU/ml for all components), the post inactivation specifications (MAT for APP and OD540nm for PM) and the serological potency assay.
Danish: Disse test (modificeret agglutinationstest (MAT) for APP og absorbans på 540 nm for PMA) var blevet valideret, men der blev imidlertid rejst yderligere spørgsmål vedrørende sammenhængen mellem de indledende antigenniveauer inden inaktivering (CFU/ml for alle komponenter), specifikationerne efter inaktivering (MAT for APP og absorbans på 540 nm for PMA) og den serologiske styrkeanalyse.
English: Concerning the absence of challenge with APP serotype 11, part of the applicant's view is that all three Apx groups are represented in the vaccine.
Danish: Hvad angår den manglende challengeundersøgelse med APP serotype 11, skyldes dette ifølge ansøgeren til dels, at alle tre Apx-grupper er repræsenteret i vaccinen.
English: Consequently, there were concerns that batch to batch consistency could not be ensured.
Danish: Der blev som følge heraf ytret betænkeligheder ved, hvorvidt der kunne sikres ensartethed fra batch til batch.
English: Consequently it was agreed that the APP serotypes in the product are relevant and therefore inclusion of the APP components in the vaccine was adequately justified.
Danish: Det blev således vedtaget, at APPserotyperne i lægemidlet er relevante, og at medtagelse af APP-komponenterne i vaccinen var tilstrækkeligt begrundet.
English: In addition, it was considered that the field studies were not adequate and lacked direct confirmation of the presence of APP or appropriate monitoring of clinical signs or other efficacy parameters.
Danish: Feltundersøgelserne betragtedes endvidere som utilstrækkelige, og der manglede direkte bekræftelse af tilstedeværelsen af APP og passende overvågning af kliniske symptomer eller andre effektivitetsparametre.
English: The lack of convincing data in support of the efficacy of P.multocida was considered a particular weakness.
Danish: Manglen på overbevisende data til underbyggelse af effektiviteten af Pasteurella multocida blev i særlig grad betragtet som en svaghed.
English: The Applicant considers that the pathological changes seen in the lungs are different due to Actinobacillus pleuropneumoniae compared to Pasteurella multocida.
Danish: Ansøgeren finder, at de patologiske forandringer i lungerne er forskellige, når Actinobacillus pleuropneumoniae sammenlignes med Pasteurella multocida.
English: Concerns over A.pleuropneumoniae efficacy related to a lack of confirmation of Apx toxins in the finished product and absence of specific challenge studies with APP serotype 11.
Danish: Betænkeligheder i forbindelse med effektiviteten af A. pleuropneumoniae vedrørte manglende bekræftelse af Apx-toksiner i det færdige produkt og manglende specifikke challengeundersøgelser med APP serotype 11.
English: The applicant has shown that product containing the proposed upper limit of formaldehyde has not given rise to significant adverse reactions during single, repeated and overdose studies or during field use, nor during safety studies in pregnant sows.
Danish: Ansøgeren har vist, at lægemidler indeholdende den foreslåede øvre grænse for formaldehyd ikke har givet anledning til væsentlige bivirkninger i forbindelse med undersøgelser med enkeltdosis, gentagne doser eller overdosis eller ved anvendelse i feltundersøgelser eller i sikkerhedsundersøgelser hos drægtige søer.
English: Due to concerns related to correlation between serological response against P. multocida and protection, Spain considers that because of a lack of correlation there is also no proven correlation between the batch potency test in rabbits and efficacy in pigs for this antigen.
Danish: På grund af betænkeligheder ved korrelationen mellem serologisk respons mod P. multocida og beskyttelse vurderer Spanien, at der på grund af manglende korrelation heller ikke er nogen påvist korrelation mellem batch-styrketesten hos kaniner og effektiviteten hos svin af dette antigen.
English: Strains of Actinobacillus pleuropneumoniae producing Apx I, ApxII and ApxIII toxins:
Danish: Stammer af Actinobacillus pleuropneumoniae, der producerer Apx I-, ApxII- og ApxIIItoksiner:
English: However, whilst these provided more detailed information than had been previously available these were not sufficient to confirm the validity of the studies for the purposes of supporting a efficacy claim for P.multocida.
Danish: Selv om disse gav adgang til mere detaljerede informationer, end der før havde været til rådighed, var de ikke tilstrækkelige til at bekræfte validiteten af undersøgelserne med hensyn til at støtte en påstand om effektivitet for P. multocida.
English: The field data were deficient and it was not clear that the presence of PMA in the vaccine had any specific benefit.
Danish: Dataene fra feltundersøgelserne var mangelfulde, og det påvistes ikke tydeligt, at tilstedeværelsen af PMA i vaccinen havde nogen specifik fordel.
English: For immunization of piglets the first dose (2ml) should be given at age 6-8 weeks, followed by a second dose (2ml) 14-21 days later.
Danish: For immunisering af smågrise gives den første dosis (2 ml), når smågrisene er 6-8 uger gamle, efterfulgt af anden dosis (2 ml) 14-21 dage senere.
English: The efficacy of the P.multocida component should be demonstrated through the provision of appropriate controlled studies clearly demonstrating that the presence of PMA in the vaccine has a specific benefit.
Danish: Effektiviteten af P. multocida-komponenten skal påvises gennem hensigtsmæssige kontrollerede undersøgelser, som tydeligt viser, at tilstedeværelsen af PMA i vaccinen udgør en specifik fordel.
English: The conditions for lifting the suspension are set out in Annex III.
Danish: Betingelserne for ophævelse af suspenderingen af markedsføringstilladelsen findes i bilag III.
English: - consequently, the CVMP considered that in the absence of any demonstrated benefit of this component the risk-benefit analysis for the P. multocida serotype A component must be negative, therefore presenting an unacceptable serious risk to human or animal health or to the environment.
Danish: - CVMP fandt derfor, at da der ikke kunne påvises nogen fordele ved denne komponent, må risk/benefit-forholdet for P. multocida serotype A-komponenten nødvendigvis være negativt, og denne komponent udgør derfor en uacceptabel alvorlig risiko for menneskers og dyrs sundhed og for miljøet ─
English: APPM Respipharm is a multi-component formaldehyde inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (Serotypes 2, 9 and 11) and one strain of Pasteurella multocida (Serotype A), and includes aluminium hydroxide gel as adjuvant.
Danish: APPM Respipharm er en multikomponent formaldehyd-inaktiveret helcelle-bakterievaccine, der indeholder tre stammer af Actinobacillus pleuropneumoniae (serotype 2, 9 og 11) og en stamme af Pasteurella multocida (serotype A), og som er tilsat aluminiumhydroxidgel som adjuvans.
English: Efficacy issues:
Danish: Effektivitetsaspekter:
English: Consequently it was agreed that the level of formaldehyde included in the product was acceptable.
Danish: Det blev således vurderet, at formaldehydniveauet i lægemidlet var acceptabelt.
English: Administration is by two intramuscular injections separated by 2-3 weeks.
Danish: Det indgives som to intramuskulære injektioner med 2-3 uger imellem.
English: Notwithstanding the committees reservations concerning the deficiencies in the studies it was also noted that the Applicant/MAH had not provided data in support of the claimed onset and duration of protection for P. multocida.
Danish: Til trods for udvalgets forbehold med hensyn til manglerne i undersøgelserne blev det også bemærket, at ansøgeren/indehaveren af markedsføringstilladelsen ikke havde fremsendt data til underbyggelse af den påståede indtræden og varighed af beskyttelse for P. multocida.
English: In addition, it is considered that on animal welfare grounds, additional challenge studies with APP Serotype 11 are unnecessary and should not be requested.
Danish: Det vurderes endvidere, at yderligere challengeundersøgelser med APP serotype 11 på baggrund af dyrevelfærd er unødvendige, og at der ikke skal anmodes om sådanne.
English: The Note for Guidance on requirements for combined veterinary vaccines2, states “Deletion of challenges is only acceptable in rare cases and must be fully justified.”, and in addition Annex I to Directive 2001/82/EC as amended (Part 4 Efficacy tests, Field trials), which states that “Where laboratory trials cannot be supportive of efficacy, the performance of field trials alone may be acceptable.”.
Danish: I vejledningsnotatets krav til kombinerede veterinære vacciner2 fastslås det, at udeladelse af challengeundersøgelser kun accepteres i sjældne tilfælde og skal fuldt ud begrundes, og i bilag I til direktiv 2001/82/EF, med senere ændringer (Del 4, Afprøvning af effektivitet, Feltforsøg), fastslås følgende: "Hvis effektiviteten af produktet ikke kan belyses gennem laboratorieforsøg, kan det tillades, at der alene gennemføres feltundersøgelser."
English: At the age of 6-8 weeks.
Danish: Når de er 6-8 uger gamle Revaccination:
English: There were concerns as to how the results had been assessed, in particular how mortality and lung confiscations had been definitively assigned to A.pleuropneumoniae.
Danish: Der opstod betænkeligheder ved, hvordan resultaterne var blevet vurderet, navnlig hvordan dødelighed og lungekonfiskationer definitivt havde kunnet tilskrives A. pleuropneumoniae eller P. multocida.
English: The product is indicated for use in pigs (sows and weaned piglets) from 6 weeks of age, intended to induce active immunization of sows and piglets against pleuropneumonia caused by Actinobacillus pleuropneumoniae and against secondary infection by Pasteurella multocida.
Danish: Lægemidlet er indiceret til brug hos svin (søer og fravænnede smågrise) fra 6-ugers-alderen og er beregnet til at inducere aktiv immunisering af søer og smågrise over for ondartet lungesyge forårsaget af Actinobacillus pleuropneumoniae og over for sekundær infektion med Pasteurella multocida.
English: Furthermore, there was a need to clarify the relevance of the APPM Respipharm vaccine batch(es) used in the field studies.
Danish: Der var endvidere behov for at klarlægge relevansen af den batch eller de batcher af APPM Respipharm-vaccine, der blev anvendt i feltundersøgelserne.
English: However, the committee had significant concerns related to the quality and validity of the field studies provided in support of the efficacy of P.multocida.
Danish: Men udvalget havde imidlertid betænkeligheder vedrørende kvaliteten og validiteten af de feltundersøgelser, der skulle underbygge effektiviteten af P. multocida.
English: The Applicant/Marketing Authorisation Holder (MAH) had developed additional in-process tests to control antigen levels after inactivation.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen havde udviklet yderligere produktionskontrol for at kontrollere antigenniveauerne efter inaktivering.
English: Some of the field data presented by the Applicant/MAH confirmed that the antigen levels were in those studies at or below the antigen levels proposed as the product minima.
Danish: Nogle af de feltdata, som ansøgeren/indehaveren af markedsføringstilladelsen fremlagde, bekræftede, at antigenniveauet i disse undersøgelser lå på samme niveau eller under de foreslåede minimumsantigenniveauer.
English: For immunization of sows the first dose (3ml) should be given 4-5 weeks before the expected farrowing date, with the second injection (3ml) at least 2 weeks before the expected farrowing date.
Danish: For immunisering af søer gives den første dosis (3 ml) 4-5 uger inden forventet faring, og den anden injektion gives (3 ml) gives mindst 2 uger inden forventet faring.
English: - the CVMP considered that these deficiencies are such that it is considered that no data have been provided in support of the efficacy of the P. multocida serotype A component.
Danish: - CVMP fandt, at disse mangler er af en sådan art, at det vurderes, at der ikke foreligger nogen data til støtte for effektiviteten af P. multocida serotype A-komponenten.
English: In view of the fact that the Applicant/MAH intended to demonstrate the efficacy of the PMA component by comparison of the efficacy of APPM Respipharm compared to comparator products there was a need to clarify the composition of the other vaccine (containing A. pleuropneumoniae only).
Danish: I betragtning af, at ansøgeren/indehaveren af markedsføringstilladelsen agtede at påvise effektiviteten af PMA-komponenten ved at foretage en sammenligning af effektiviteten af APPM Respipharm og sammenlignelige lægemidler, var det nødvendigt at præcisere sammensætningen af den anden vaccine (kun indeholdende A. pleuropneumoniae).
English: The Applicant/MAH provided the requested clarification, which confirmed the statistical analysis that had been applied.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen fremsendte de krævede præciseringer, som bekræftede, hvilken statistisk analyse der var blevet anvendt.
English: The Applicant/MAH clarified the composition of the other comparator products and confirmed that they had been administered according to the recommended schedule.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen redegjorde for sammensætningen af de andre sammenlignelige lægemidler og bekræftede, at de var blevet indgivet i overensstemmelse med den anbefalede plan.
English: The Applicant/MAH had conducted further analysis and validation in support of the in-process and finished product testing specifications, which could be considered adequate, provided some points of clarification were adequately addressed.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen havde foretaget yderligere analyse og validering til støtte for specifikationerne for produktionskontrollen og kontrollen af det færdige produkt, som kunne betragtes som tilstrækkeligt, under forudsætning af at visse punkter blev præciseret.
English: The Applicant/MAH confirmed that the diagnosis was conducted by experienced veterinary practitioners based on previous clinical history and on post mortem findings in cases of mortality.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen bekræftede, at diagnosen var foretaget af erfarne dyrlæger på baggrund af anamnese og post mortem-resultater med hensyn til dødelighed.
English: First injection:
Danish: Fravænnede smågrise: Første injektion:
English: Concerning the surveillance field study the Applicant/MAH gave additional data about the batches used, which were by mistake omitted.
Danish: Med hensyn til overvågningsfeltundersøgelsen fremlagde ansøgeren/indehaveren af markedsføringstilladelsen supplerende data om de anvendte batcher, som ved en fejltagelse var udeladt.
English: The Applicant/MAH had justified the absence of specific challenge studies with P.multocida on the basis that there are recognised difficulties in conducting meaningful challenge studies.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen havde begrundet fraværet af specifikke challengeundersøgelser med P. multocida i, at der er anerkendte vanskeligheder i forbindelse med at foretage meningsfulde challengeundersøgelser.
English: The analysis had looked at the frequency of mortality and lung confiscations at slaughter (indicative of the presence of lesions) caused by either APP or P.multocida in pigs vaccinated with APPM Respipharm.
Danish: Analysen behandlede frekvensen for dødelighed og lungekonfiskationer ved slagtning (indikation på læsioner) forårsaget af enten APP eller P. multocida hos svin vaccineret med APPM Respipharm.
English: In view of the fact that the Applicant/MAH proposed to support the efficacy of the P. multocida component with data from the field the Applicant/MAH was requested to clarify whether animals vaccinated with APPM Respipharm, competitor vaccine and unvaccinated controls had been housed together on each site, which could have allowed a valid comparison of the efficacy of the respective vaccines.
Danish: I betragtning af, at ansøgeren/indehaveren af markedsføringstilladelsen søgte at underbygge effektiviteten af P. multocida-komponenten med data fra feltundersøgelser, blev denne anmodet om at præcisere, hvorvidt dyr vaccineret med APPM Respipharm, en konkurrerende vaccine og ikkevaccinerede kontroller havde været opstaldet sammen i hvert opdræt, hvilket kunne have givet mulighed for en gyldig sammenligning af de respektive vacciners effektivitet.
English: The Note for Guidance on field trials with veterinary vaccines3 indicates “The environment in which the two groups of animals are housed shall be as equivalent as possible (i.e. same farm/barn/batch) or at least as similar as possible (e.g. same farm/different barn/same batch).” It was confirmed that according to the study protocol the groups of pigs vaccinated with the different vaccines had been housed at the same farm in different halls (barns) which is acceptable.
Danish: I vejledningsnotatet om feltundersøgelser af veterinære vacciner3 fastslås det, at "det miljø, i hvilket de to grupper af dyr opstaldes, skal så vidt muligt være ens (dvs. samme gård/stald/batch) eller i det mindste så ens som muligt (dvs. samme gård/anden stald/samme batch).
English: In addition, argumentation has been presented which supports the importance of Apx toxins as important antigens in mediating protection, which is also supported by the requirements of the specific Ph. Eur.
Danish: Der er endvidere blevet fremført argumentation, som understøtter betydningen af Apx-toksiner som vigtige antigener i formidling af beskyttelse, hvilket også støttes af kravene i Den Europæiske Farmakopés specifikke monografi (2008/1360).
English: First injection 4-5 weeks before expected farrowing.
Danish: Basisvaccination: Første injektion 4-5 uger inden forventet faring
English: ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR REFUSAL OF THE GRANTING OF THE MARKETING AUTHORISATIONS AND FOR THE SUSPENSION OF EXISTING MARKETING AUTHORISATION
Danish: BILAG II FAGLIGE KONKLUSIONER OG BEGRUNDELSER FOR AFSLAG PÅ MARKEDSFØRINGSTILLADELSEN OG FOR SUSPENDERING AF EKSISTERENDE MARKEDSFØRINGSTILLADELSE
English: the CVMP has recommended the refusal of granting the Marketing Authorisations and the suspension of the existing Marketing Authorisation.
Danish: anbefalede udvalget at give afslag på ansøgningerne om markedsføringstilladelse og at suspendere den eksisterende markedsføringstilladelse.
English: Concerning the link to the efficacy of P.multocida the Applicant/MAH was requested to provide further information on the batches of vaccine used during the field studies and further clarification on the details of the studies sufficient to substantiate a claim for the efficacy of the P.multocida component.
Danish: Hvad angår forbindelsen til effektiviteten af P. multocida, blev ansøgeren/indehaveren af markedsføringstilladelsen anmodet om at fremsende yderligere oplysninger om de vaccine-batcher, der blev brugt under feltundersøgelserne, samt yderligere præcisering af undersøgelsernes detaljer i tilstrækkelig grad til at underbygge en påstand om P. multocida-komponentens effektivitet.
English: Applicant or Marketing Authorisation Holder
Danish: Medlemsstat Ansøger eller indehaver af markedsføringsti lladelse
English: The Applicant/MAH provided information on the antigen content of the batches of vaccine used in the field studies.
Danish: Ansøgeren/indehaveren af markedsføringstilladelsen fremsendte informationer om antigenindholdet i de vaccinebatcher, der blev anvendt i feltundersøgelserne.
English: The data have been collected over a number of years (at least 2004-2008) and included a total of 163,061 pigs, of which 93,460 had been vaccinated with APPM Respipharm, 37,541 had been treated with an APP vaccine without P.multocida, and 32,060 pigs had not been vaccinated.
Danish: Der er endvidere indsamlet data fra feltundersøgelser med sammenligning af de kliniske resultater hos svin med luftvejssygdomme i svineopdræt, hvor APP og P. multocida var til stede samtidig, og hvor svinene er blevet vaccineret med enten APPM Respipharm eller et konkurrerende lægemiddel kun indeholdende APP. Dataene er blevet indsamlet over en årrække (mindst 2004-2008) og omfattede i alt 163.061 svin, hvoraf 93.460 var blevet vaccineret med APPM Respipharm, 37.541 var blevet behandlet med en APP-vaccine uden P. multocida, og 32.060 svin var ikke blevet vaccineret.
English: The major point of refusal related to the lack of evidence to support the efficacy of the P.multocida component.
Danish: Det hovedpunkt, der dannede grundlag for afslaget, vedrørte den manglende dokumentation for effektiviteten af P. multocida-komponenten.